Gisbert Selke
Overview
Explore the profile of Gisbert Selke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
409
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, et al.
Biomed Res Int
. 2023 Apr;
2023:9757348.
PMID: 37065720
[This corrects the article DOI: 10.1155/2021/9996193.].
2.
Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, et al.
Biomed Res Int
. 2021 Oct;
2021:9996193.
PMID: 34676266
Background: Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with...
3.
Godman B, Hill A, Simoens S, Selke G, Krulichova I, Dias C, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2021 Feb;
21(4):527-540.
PMID: 33535841
: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of...
4.
Moorkens E, Barcina Lacosta T, Vulto A, Schulz M, Gradl G, Enners S, et al.
Pharmaceuticals (Basel)
. 2020 Oct;
13(10).
PMID: 33096709
Drug budget and prescription control measures are implemented regionally in Germany, meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region. We examine regional market dynamics of tumor...
5.
Pontes C, Zara C, Torrent-Farnell J, Obach M, Nadal C, Vella-Bonanno P, et al.
Appl Health Econ Health Policy
. 2019 Nov;
18(1):5-16.
PMID: 31696433
The potential benefits of early patient access to new medicines in areas of high unmet medical need are recognised, but uncertainties concerning effectiveness, safety and added value when new medicines...
6.
Vella Bonanno P, Bucsics A, Simoens S, Martin A, Oortwijn W, Gulbinovic J, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2019 Jan;
19(3):251-261.
PMID: 30696372
In January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A...
7.
Godman B, Bucsics A, Vella Bonanno P, Oortwijn W, Rothe C, Ferrario A, et al.
Front Public Health
. 2018 Dec;
6:328.
PMID: 30568938
There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever...
8.
Vella Bonanno P, Ermisch M, Godman B, Martin A, Van Den Bergh J, Bezmelnitsyna L, et al.
Front Pharmacol
. 2017 Sep;
8:497.
PMID: 28878667
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines...
9.
Ermisch M, Bucsics A, Vella Bonanno P, Arickx F, Bybau A, Bochenek T, et al.
Front Pharmacol
. 2016 Oct;
7:305.
PMID: 27733828
Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope...
10.
Matusewicz W, Godman B, Bak Pedersen H, Furst J, Gulbinovic J, Mack A, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2015 Sep;
15(5):755-8.
PMID: 26368060
No abstract available.